-
公开(公告)号：US20210171637A1
公开(公告)日：2021-06-10
申请号：US16819036
申请日：2020-03-13
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Debra Chao , Kamel Izeradjene , Andrew S. Judd , Andrew C. Phillips , Andrew J. Souers , Archana Thakur , Milan Bruncko
IPC: C07K16/28 , A61K47/68 , A61K31/498 , A61K31/437 , A61K31/519
Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
公开(公告)号：US20200002421A1
公开(公告)日：2020-01-02
申请号：US16308622
申请日：2017-06-07
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Milan Bruncko , Debra Chao , Kamel Izeradjene , Andrew S. Judd , Andrew C. Phillips , Andrew J. Souers , Archana Thakur , George Doherty , Robin R. Frey , Xiaohong Song , Gerard M. Sullivan , Zhi-Fu Tao
Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
公开(公告)号：US20190134216A1
公开(公告)日：2019-05-09
申请号：US16154229
申请日：2018-10-08
Applicant: AbbVie Inc.
Inventor： Edward B. Reilly , Andrew C. Phillips , Lorenzo Benatuil , Chung-Ming Hsieh , Jennifer Perez
Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
公开(公告)号：US20150337042A1
公开(公告)日：2015-11-26
申请号：US14664453
申请日：2015-03-20
Applicant: ABBVIE INC.
Inventor： Edward B. Reilly , Andrew C. Phillips , Lorenzo Benatuil , Fritz G. Buchanan , Jonathan A. Meulbroek , Chung-Ming Hsieh , Jennifer Perez
CPC classification number: A61K47/6811 , A61K47/6803 , A61K47/6847 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6863 , A61K47/6865 , A61K47/6889 , A61K2039/505 , C07K14/00 , C07K16/2863 , C07K16/30 , C07K16/3023 , C07K16/3046 , C07K16/3053 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
Abstract translation: 本发明涉及抗表皮生长因子（EGFR）抗体和抗体药物偶联物（ADC），包括使用所述抗体和ADC的组合物和方法。
-
公开(公告)号：US20140170152A1
公开(公告)日：2014-06-19
申请号：US14073479
申请日：2013-11-06
Applicant: Abbvie Inc.
Inventor： Chung-ming Hsieh , Lorenzo Benatuil , Yuliya Kutskova , John Memmott , Jennifer Perez , Suju Zhong , Carrie Goodreau , Anca Clabbers
IPC: C07K16/24 , A61K45/06 , A61K39/395
CPC classification number: C07K16/241 , A61K39/3955 , A61K45/06 , A61K47/6847 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2317/92 , G01N33/6863
Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
Abstract translation: 公开了与肿瘤坏死因子-α（TNF-α）结合的分离的结合蛋白，例如结合肿瘤坏死因子-α（TNF-α）的抗体或其抗原结合部分以及相关的基于抗体的组合物和分子。 还公开了包含抗体的药物组合物，以及使用抗体的治疗和诊断方法。
-
Patent Agency Ranking
公开(公告)号：US20140093521A1
公开(公告)日：2014-04-03
申请号：US14090778
申请日：2013-11-26
Applicant: ABBVIE INC.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
IPC: A61K39/395 , A61K45/06 , C07K16/18 , C07K7/06 , C07K7/08
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
Abstract translation: 描述了改进的DLL4结合蛋白，包括抗体，CDR-移植抗体，人抗体和DLL4结合片段，以高亲和力结合DLL4的蛋白质，以及中和DLL4活性的DLL4结合蛋白。 DLL4结合蛋白可用于治疗或预防癌症和肿瘤，特别是用于治疗或预防肿瘤血管生成和/或其它血管发生依赖性疾病，例如眼新生血管形成或以异常DLL4表达或活性为特征的血管发生非依赖性疾病，例如自身免疫 包括多发性硬化的疾病。
-
公开(公告)号：US20250163159A1
公开(公告)日：2025-05-22
申请号：US18670261
申请日：2024-05-21
Applicant: AbbVie Inc.
Inventor： Edward B. Reilly , Andrew C. Phillips , Lorenzo Benatuil , Chung-Ming Hsieh , Jennifer Perez
Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
公开(公告)号：US20200002432A1
公开(公告)日：2020-01-02
申请号：US16308755
申请日：2017-06-08
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Milan Bruncko , George Doherty , Robin R. Frey , Andrew S. Judd , Yingchun Li , Andrew Mccluskey , Andrew C. Phillips , Darren C. Phillips , Jane Seagal , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao
Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
-
公开(公告)号：US10093733B2
公开(公告)日：2018-10-09
申请号：US14967260
申请日：2015-12-11
Applicant: AbbVie Inc.
Inventor： Lorenzo Benatuil , Kangwen Deng , Denise Karaoglu Hanzatian , Maria A. Argiriadi
IPC: C07K16/28 , C07K16/46 , G01N33/53 , C07K14/705 , A61K39/395 , A61K45/06 , G01N33/566 , A61K38/00 , A61K47/68 , A61K39/00
Abstract: The disclosure provides binding proteins that specifically bind to LRP-8 and optionally cross the blood brain barrier (BBB), localize to the brain and/or localize to the spinal cord.
-
公开(公告)号：US09469688B2
公开(公告)日：2016-10-18
申请号：US14822329
申请日：2015-08-10
Applicant: ABBVIE INC.
Inventor： Lorenzo Benatuil , Erwin R. Boghaert , Jijie Gu , Maria Harris , Jonathan A. Hickson , Chung-Ming Hsieh , Yuliya Kutskova , Yingchun Li , Zhihong Liu , Susan Morgan-Lappe
IPC: C07H21/04 , C07K16/22 , C07K14/47 , C07K16/18 , A61K39/395 , A61K45/06 , C07K7/06 , C07K7/08 , A61K39/00
CPC classification number: C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.
-
-
-
-
-
-
-
-
-
Search Results
44
records
(took 0.045 seconds)
